Saudi Arabia HIV Therapeutics Market Analysis Report [2022-30]

Saudi Arabia HIV Therapeutics Market Analysis

$ 3999

The Saudi Arabia HIV therapeutics market is expected to reach $325.09 Mn by 2030, up from $233.92 Mn in 2022, with a CAGR of 4.2% from 2022 to 2030. Local players such as SPIMACO, Tabuk Pharmaceuticals, and Jamjoom Pharma dominate the HIV therapeutics market in Saudi Arabia. Government policies, funding, and initiatives to manage HIV infections in the country propel market growth. The HIV therapeutics market in Saudi Arabia is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10SAPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Vishwa Modhia

Buy Now

Saudi Arabia HIV Therapeutics Market Analysis Summary

The Saudi Arabia HIV therapeutics market is expected to reach $325.09 Mn by 2030, up from $233.92 Mn in 2022, with a CAGR of 4.2% from 2022 to 2030.

Saudi Arabia is a Middle Eastern country that borders the Persian Gulf and the Red Sea. According to the most recent WHO data published in 2020, the number of HIV/AIDS deaths in Saudi Arabia reached 192, accounting for 0.14 % of all deaths. Saudi Arabia ranks 124th in the world with an age-adjusted death rate of 0.50 per 100,000 population. With 12,000 HIV cases in 2020, the adult prevalence of HIV/AIDS in Saudi Arabia was less than 0.1%.

In Saudi Arabia, the Ministry of Health is the primary government agency in charge of HIV treatment and care. The shift to a more privatized and comprehensive healthcare system will increase demand for both patented and generic drugs. In 2018, Saudi Arabia spent 5.5 % of its GDP on healthcare.

saudi arabia HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

Saudi Arabia spends 60% of the Gulf Cooperation Council (GCC) countries' healthcare budgets, and the sector remains a top priority for the Saudi government. It spent $36.8 Bn on healthcare and social development in 2022, accounting for 14.4 % of its budget and ranking third after education and the military. The Saudi government is planning to privatize the healthcare sector. This has the potential to uplift the HIV therapeutics market in Saudi Arabia.

Market Restraints

The progress toward meeting the WHO 90-90-90 goals for HIV not only in the Kingdom of Saudi Arabia but also in the MENA region, which is that 90 % is diagnosed, % are receiving treatment, and 90 % is under viral control, is not really being systematically monitored. This may deter new players from entering the Saudi HIV therapeutics market.

Competitive Landscape

Key Players

Jamjoom Pharma (SAU)
Tabuk Pharmaceuticals (SAU)
SPIMACO (SAU)
Gilead Sciences
AbbVie
Roche

Healthcare Regulations and Reimbursement Policies

The Saudi Food and Drug Authority (SFDA) regulates HIV therapeutics in Saudi Arabia. The SFDA is in charge of evaluating and approving all medications, including HIV drugs, based on their safety, efficacy, and quality. In addition, the SFDA establishes standards for drug manufacturing and distribution in Saudi Arabia. HIV medications are prescription-only medications that can only be obtained from licenced pharmacies or healthcare facilities. Furthermore, the Ministry of Health oversees HIV treatment and care in Saudi Arabia, and eligible individuals have access to antiretroviral therapy through government-run health centres.

In Saudi Arabia, the Ministry of Health is the primary government agency in charge of HIV treatment and care, including the reimbursement of antiretroviral therapy and other HIV-related medical services. The Ministry of Health runs government-run health centres across the country that provide free antiretroviral therapy to HIV-positive individuals who meet medical and financial criteria. The Ministry of Health also establishes national guidelines and standards for HIV treatment and care, as well as oversees the distribution of HIV drugs and other medical supplies to healthcare facilities.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.